Sanofi Pasteur Inc.

Connaught Laboratories Limited

Aventis Pasteur Limited

Robert P Ryall

Robert S Becker

Karen S Biscardi

Patrick McVerry

The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteriaThe vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides fromserogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety ofstrains in children as well as adults.

Multivalent meningococcal polysaccharide-protein conjugate vaccine

The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides fromserogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety ofstrains in children as well as adults.

Disclosed and claimed are a method for the covalent attachment of poly- and oligosaccharides to protein molecules via hydrogen peroxide depolymerization of the polysaccharide units, followed by attachment of the depolymerized polysaccharide chain to the amino acid groups of a protein of interest through a linker molecule, and products therefrom, and methods for using the products.

Method for the covalent attachment of polysaccharides to protein

The dosage response of humans to conjugate vaccines comprising a bacterial polysaccharide and a strongly-immunogenic carrier protein is determined in animals by coadministering to the animal unconjugated strongly-immunogenic carrier protein in an amount corresponding, on a weight-related basis, to that administered to the human.

Growing community of inventors

Stroudsburg, PA, United States of America

Robert P Ryall